ELAT

Elanco Animal Health Incorporat [ELAT] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ELAT Stock Summary

Top ELAT Correlated Resources

ELAT


Top 10 Correlated ETFs

ELAT


Top 10 Correlated Stocks

ELAT


In the News

01:00 08 Dec 2022 ELAT

Dr. Marijn Dekkers Joins AgBiome As a Strategic Advisor

AgBiome, a leader in developing innovative products from the Earth's microbial communities, announced Dr. Marijn Dekkers as the company's newest advisor. Dr. Dekkers is the founder and chairman of Novalis LifeSciences, an investment and advisory firm for the Life Science industry. He formerly served as the CEO of Bayer AG, and before that, Thermo Fisher Scientific Inc. He supports AgBiome as an industry advisor and board observer.

07:04 08 Dec 2022 ELAT

Top Insider Buys Highlight for the Week of August 7

The largest Insider Buys this week were for Boeing Co., IQVIA Holdings Inc., Schlumberger Ltd. and Elanco Animal Health Inc. Continue reading...

01:43 08 Dec 2022 ELAT

Elanco CEO on $7.6B purchase of Bayer Animal Health

Elanco has closed its $7.6 billion acquisition of Bayer Animal Health. Elanco CEO Jeff Simmons joins Yahoo Finance’s Brian Sozzi and Alexis Christoforous to discuss.

10:00 08 Dec 2022 ELAT

Elanco Closes Acquisition of Bayer Animal Health

Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has closed the acquisition of Bayer Animal Health. The transaction, valued at $6.89 billion, expands Elanco’s scale and capabilities, positioning the company for the long term as a leader in the attractive, durable animal health industry.

10:30 08 Dec 2022 ELAT

Elanco Animal Health Reports 2020 Second Quarter Results

Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the second quarter of 2020. The performance reflects the reduction of channel inventory and lower levels of demand resulting from the COVID-19 pandemic. Elanco's innovation, portfolio, and productivity strategy continues to be the focus, and its long-term industry fundamentals and durability remain intact.

02:00 08 Dec 2022 ELAT

Jason Kuhlemeier Joins AgBiome as VP of Marketing

AgBiome, a leader in developing innovative products from the Earth's microbial communities, announced Jason Kuhlemeier has joined the company as Vice President of Marketing. Kuhlemeier has a long successful track record of working in the agriculture industry.

02:00 08 Dec 2022 ELAT

Gerald Coward Joins AgBiome as CFO

AgBiome®, a leader in developing innovative products from the Earth's microbial communities, announced Gerald Coward has joined the company as its Chief Financial Officer. Gerald will lead the finance team from the company's headquarters in Research Triangle Park, NC, effective immediately.

04:40 08 Dec 2022 ELAT

FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Elanco Animal Health Incorporated and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Securities and Exchange Commission.

03:00 08 Dec 2022 ELAT

DEADLINE ALERT for ELAN, R, and HBB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, July 20, 2020 -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following.

03:00 08 Dec 2022 ELAT

ELAN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Elanco Animal Health Incorporated and Lead Plaintiff Deadline: July 20, 2020

New York, New York--(Newsfile Corp. - July 20, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE: ELAN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Elanco securities between January 10, 2020 and May 6, 2020, inclusive (the ''Class Period''). Such investors are encouraged to join this case by ...

ELAT Financial details

Company Rating
Buy
Market Cap
0
Income
-120M
Revenue
4.54B
Book val./share
13.81
Cash/share
0.94
Dividend
2.5
Dividend %
12.32%
Employees
-
Optionable
No
Shortable
Yes
Earnings
-
P/E
-82.56
Forward P/E
-
PEG
22.65
P/S
2.18
P/B
1.47
P/C
21.61
P/FCF
21.26
Quick Ratio
0.92
Current Ratio
1.96
Debt / Equity
0.82
LT Debt / Equity
0.82
-
-
EPS (TTM)
-0.81
EPS next Y
-
EPS next Q
-
EPS this Y
-23.62%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
10.53%
Revenue Q/Q
-12.66%
EPS Q/Q
122.22%
-
-
-
-
SMA20
-4.76%
SMA50
-9.09%
SMA100
-39.39%
Inst Own
0.61%
Inst Trans
-0.34%
ROA
-1%
ROE
-2%
ROC
0.03%
Gross Margin
56%
Oper. Margin
9%
Profit Margin
-3%
Payout
-1018%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
18.4-45.79
52W High
-54.87%
52W Low
+12.83%
RSI
51
Rel Volume
0.18
Avg Volume
19.77K
Volume
3.61K
Perf Week
-2.07%
Perf Month
-3.47%
Perf Quarter
-37.72%
Perf Half Y
-46.55%
-
-
-
-
Beta
-
-
-
Volatility
0.39%, 0.8%
Prev Close
0.12%
Price
20.31
Change
-0.34%

ELAT Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2019-12-312020-12-31 2021-12-31
Revenue per share
000
Net income per share
000
Operating cash flow per share
000
Free cash flow per share
000
Cash per share
000
Book value per share
000
Tangible book value per share
000
Share holders equity per share
000
Interest debt per share
000
Market cap
000
Enterprise value
2.02B5.63B5.68B
P/E ratio
000
Price to sales ratio
000
POCF ratio
000
PFCF ratio
000
P/B Ratio
000
PTB ratio
000
EV to sales
0.661.721.19
Enterprise value over EBITDA
4.29-1.06K14.76
EV to operating cash flow
9.02-137.3711.76
EV to free cash flow
75.69-16.0119.86
Earnings yield
000
Free cash flow yield
000
Debt to equity
0.420.660.8
Debt to assets
0.380.520.54
Net debt to EBITDA
4.29-1.06K14.76
Current ratio
2.91.651.99
Interest coverage
4.69-0.511.28
Income quality
3.30.07-1.02
Dividend Yield
000
Payout ratio
000
Sales general and administrative to revenue
0.250.30
Research and developement to revenue
0.090.10.08
Intangibles to total assets
0.610.710.71
Capex to operating cash flow
-0.887.58-0.41
Capex to revenue
-0.06-0.09-0.04
Capex to depreciation
-0.63-0.6-0.28
Stock based compensation to revenue
0.020.010.01
Graham number
000
ROIC
0.0500.02
Return on tangible assets
0.02-0.11-0.1
Graham Net
000
Working capital
1.55B1.34B1.63B
Tangible asset value
74.5M-4.14B-4.22B
Net current asset value
-1.07B-5.8B-5.67B
Invested capital
0.420.720.84
Average receivables
983.3M1.08B1.05B
Average payables
361.8M501M459.5M
Average inventory
1.31B1.58B1.48B
Days sales outstanding
105.77120.0678.75
Days payables outstanding
55.26109.7271.49
Days of inventory on hand
260.83345.62234.84
Receivables turnover
3.453.044.64
Payables turnover
6.613.335.11
Inventory turnover
1.41.061.55
ROE
0.01-0.07-0.06
Capex per share
000

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
Revenue per share
2.322.282.512.412.1
Net income per share
-0.21-0.20.1-0.05-0.1
Operating cash flow per share
0.180.46-0.130.640.39
Free cash flow per share
0.130.27-0.180.570.29
Cash per share
0.931.310.71.040.94
Book value per share
15.7415.4515.614.6213.81
Tangible book value per share
-8.86-8.65-7.99-7.82-7.65
Share holders equity per share
15.7415.4515.614.6213.81
Interest debt per share
13.113.0612.6812.5512.21
Market cap
24.34B21.79B19.88B15.65B10.21B
Enterprise value
30.22B27.48B25.67B21.2B15.65B
P/E ratio
-58.5-56.17103.55-177.82-52.1
Price to sales ratio
21.5219.5816.2313.39.93
POCF ratio
273.4497.73-320.6650.1554.03
PFCF ratio
380.26165.11-225.9256.0971.42
P/B Ratio
3.172.892.612.191.51
PTB ratio
3.172.892.612.191.51
EV to sales
26.7224.6920.9618.0215.23
Enterprise value over EBITDA
302.18254.485.8696.3874.19
EV to operating cash flow
339.52123.21-414.0867.9682.82
EV to free cash flow
472.15208.14-291.7476109.46
Earnings yield
00000
Free cash flow yield
00.0100.020.01
Debt to equity
0.820.80.80.840.82
Debt to assets
0.540.540.530.540.55
Net debt to EBITDA
58.8152.619.3725.2525.79
Current ratio
2.321.992.442.471.96
Interest coverage
0.870.753.422.010.87
Income quality
-0.86-2.3-1.29-14.18-3.86
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.080.080.070.070.08
Intangibles to total assets
0.720.710.710.70.7
Capex to operating cash flow
-0.28-0.410.42-0.11-0.24
Capex to revenue
-0.02-0.08-0.02-0.03-0.04
Capex to depreciation
-0.15-0.52-0.15-0.19-0.28
Stock based compensation to revenue
0.020.020.010.010.01
Graham number
8.698.315.883.855.58
ROIC
000.010.010
Return on tangible assets
-0.02-0.020.010-0.01
Graham Net
-14.19-14.04-13.79-13.19-12.9
Working capital
1.8B1.63B1.89B1.97B1.54B
Tangible asset value
-4.33B-4.22B-3.9B-3.82B-3.74B
Net current asset value
-5.72B-5.67B-5.45B-5.15B-5.05B
Invested capital
0.820.840.810.850.87
Average receivables
1.11B1.08B1.16B1.13B1.08B
Average payables
411M402M394M386M368M
Average inventory
1.36B1.35B1.34B1.33B1.34B
Days sales outstanding
86.183.1387.5886.2590
Days payables outstanding
78.1773.4871.0871.7866.74
Days of inventory on hand
247.95241.35237.82248.06255.51
Receivables turnover
1.051.081.031.041
Payables turnover
1.151.221.271.251.35
Inventory turnover
0.360.370.380.360.35
ROE
-0.01-0.010.010-0.01
Capex per share
-0.05-0.19-0.05-0.07-0.09

ELAT Frequently Asked Questions

What is Elanco Animal Health Incorporat stock symbol ?

Elanco Animal Health Incorporat is a US stock and trading under the symbol ELAT

What is Elanco Animal Health Incorporat stock quote today ?

Elanco Animal Health Incorporat stock price is $20.31 today.

Is Elanco Animal Health Incorporat stock public?

Yes, Elanco Animal Health Incorporat is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap